1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
    Neuronal Signaling
  3. iGluR
  4. iGluR Isoform
  5. iGluR Inhibitor

iGluR Inhibitor

iGluR Inhibitors (55):

Cat. No. Product Name Effect Purity
  • HY-B1102
    Evans Blue
    Inhibitor
    Evans Blue (Direct Blue 53) is a potent inhibitor of L-glutamate uptake via the membrane bound excitatory amino acid transporter (EAAT). Evans Blue is a L-glutamate and kainate receptor-mediated currents inhibitor. Evans Blue has a strong affinity towards serum albumin, making it a high molecular weight protein tracer. Evans Blue is also used to study BBB (blood-brain barrier) permeability.
  • HY-P5911
    GluN1(359-378)
    Inhibitor 99.48%
    GluN1 (359-378) is an anti-N-methyl-D-aspartate receptor (NMDAR) peptide. GluN1 (359-378) can cross the blood-brain barrier. GluN1 (359-378) can be used to study anti-NMDAR encephalitis therapy targeting the immune system.
  • HY-W015309S1
    Decanoic acid-d19
    Inhibitor 98.4%
    Decanoic acid-d199 is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects[1][2][3].
  • HY-W742957
    Pregnanolone sulfate (pyridinium)
    Inhibitor 99.78%
    Pregnanolone sulfate pyridinium is an endogenous neurosteroid that inhibits NMDA receptors and is neuroprotective.
  • HY-103230
    IEM-1460
    Inhibitor ≥98.0%
    IEM-1460 blocks both AMPA and NMDA glutamate receptor with anticonvulsant effect in vivo.
  • HY-114753A
    Neboglamine hydrochloride
    Inhibitor
    Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research.
  • HY-117483
    Gly-Pro-Glu
    Inhibitor 99.64%
    Gly-Pro-Glu is a neuroactive peptide with a potent action on acetylcholine release. Gly-Pro-Glu is the N-terminal tripeptide of insulin-like growth factor-I. Gly-Pro-Glu inhibits glutamate binds to N-methyl-D-aspartate (NMDA) receptor with an IC50 value of 14.7 μM. Gly-Pro-Glu can be used for the research of neuroprotection .
  • HY-117772
    FSC231
    Inhibitor 99.84%
    FSC231 is a PSD‐95/DLG/ZO‐1 (PDZ) domain inhibitor of PICK1. FSC231 has analgesic effects.
  • HY-139192
    Brophenexin
    Inhibitor 99.59%
    Brophenexin (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. Brophenexin shows neuroprotective activity. Brophenexin prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC50 of 2.1 μM. Brophenexin protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss.
  • HY-161137
    LQFM215
    Inhibitor 99.91%
    LQFM215 is a proline transporter (PROT) inhibitor. LQFM215 inhibits proline transport by competitively binding to the active site of PROT. LQFM215 effectively reduces hyperlocomotion and enhances social interaction.
  • HY-155811
    DQP-997-74
    Inhibitor 99.85%
    DQP-997-74 (compound 2i) is a selective inhibitor of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC50: 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases.
  • HY-108011
    Naftazone
    Inhibitor ≥99.0%
    Naftazone is a naphthoquinone derivative, it can be used for the research of venous insufciency. Naftazone protects blood vessels, increases venous tonicity and capillary resistance, and improves lymphatic and venous circulation.
  • HY-106856
    Dimiracetam
    Inhibitor ≥98.0%
    Dimiracetam is an orally active compound, with anti-neuropathic activity. Dimiracetam inhibits hypersensitivity and neurological alterations, and inhibits Sorafenib (HY-10201)-induced neuropathy in cold stimulation rat models.
  • HY-111412
    DAAO inhibitor-1
    Inhibitor 99.37%
    DAAO inhibitor-1 is a potent D-amino acid oxidase (DAAO) inhibitor with an IC50 of 0.12 μM.
  • HY-112699
    AMPA receptor modulator-1
    Inhibitor
    AMPA receptor modulator-1 is a potent, orally active and selective AMPAR regulatory protein TARP γ-8 negative modulator with a pIC50 of 9.7, more selective over GluA1/γ-2 (pIC50=5).
  • HY-107944R
    Chlorphenesin carbamate (Standard)
    Inhibitor
    Chlorphenesin carbamate (Standard) is the analytical standard of Chlorphenesin carbamate. This product is intended for research and analytical applications. Chlorphenesin carbamate is a centrally acting skeletal muscle relaxant. Chlorphenesin carbamate can be used for the research of pain and discomfort related to skeletal muscle trauma and inflammation. Chlorphenesin carbamate is a selective blocker of polysynaptic pathways at the spinal and supra-spinal levels. Antinociceptive effect.
  • HY-121100
    BZAD-01
    Inhibitor 99.81%
    BZAD-01 is a potent, selective and orally active inhibitor of NMDA NR2B subunit, with a Ki of 72 nM. BZAD-01 can improve postural asymmetry as well as Apomorphine-induced rotation.
  • HY-B0365AS
    Memantine-d6 hydrochloride
    Inhibitor ≥98.0%
    Memantine-d6 (hydrochloride) is the deuterium labeled Memantine hydrochloride. Memantine (hydrochloride) (D-145 (hydrochloride)) is a moderate affinity, uncompetitive NMDA receptor antagonist, inhibit CYP2B6 and CYP2D6 with Ki of 0.51 nM and 94.9 μM, respectively[1].
  • HY-105627A
    Profadol hydrochloride
    Inhibitor
    Profadol (CI-572) hydrochloride is a potent analgesic agent. Profadol is a µ-opioid receptor (MOR) agonist. Profadol hydrochloride activates the γ-aminobutyric acid (GABA) receptors and inhibits the N-methyl-D-aspartate (NMDA) receptor. Profadol increases the mRNA and protein expression of MOR.
  • HY-124779
    (S)-Alaproclate
    Inhibitor
    (S)-Alaproclate ((S)-GEA 654) is more potent than the R-(+)-enantiomer both in blocking the NMDA receptor currents in vitro and in antagonizing the cGMP increase in vivo.